Gilead Sciences | الأصول



Assets تغيير تاريخ
AbbVie USD 135.16B 8.26B 2024-12
Agios Pharmaceuticals USD 1.56B 107.68M 2025-03
ALKERMES USD 2.08B 26.41M 2025-03
Alnylam Pharmaceuticals USD 4.21B 26.17M 2025-03
Amgen USD 89.37B 2.47B 2025-03
Biogen USD 28.03B 16.2M 2025-03
BioMarin Pharmaceutical USD 7.15B 158.07M 2025-03
Bristol-Myers Squibb USD 92.43B 176M 2025-03
Eli Lilly USD 89.39B 10.67B 2025-03
Gilead Sciences USD 56.43B 2.56B 2025-03
GlaxoSmithKline GBP 60.71B 1.24B 2025-03
Glaxosmithkline GBP 59.46B 1.41B 2024-12
Incyte USD 5.75B 305.04M 2025-03
J&J USD 193.67B 13.57B 2025-03
Merck USD 115.12B 1.98B 2025-03
Moderna USD 12.7B 1.44B 2025-03
Neurocrine Biosciences USD 3.72B 183.7M 2024-12
Novartis USD 102.25B 1.28B 2024-12
Pfizer USD 208.03B 5.37B 2025-03
PTC Therapeutics USD 2.66B 950.36M 2025-03
Regeneron Pharmaceuticals USD 37.55B 214.2M 2025-03
Sanofi 131.89B 906M 2025-03
Sarepta Therapeutics USD 3.47B 497.79M 2025-03
United Therapeutics USD 7.74B 379.9M 2025-03
Vertex Pharmaceuticals USD 22.53B 293M 2024-12



Gilead Sciences الأصول - القيم الحالية، والبيانات التاريخية، والتنبؤات والإحصاءات والرسوم البيانية والتقويم الاقتصادي - May 2025.